{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:05:21Z","timestamp":1792130721726,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.ejim.2017.06.020","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T00:31:07Z","timestamp":1498782667000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"special_numbering":"C","title":["Primary biliary cholangitis: Old and novel therapy"],"prefix":"10.1016","volume":"47","author":[{"given":"Annarosa","family":"Floreani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Mangini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2017.06.020_bb0005","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.bpg.2011.10.005","article-title":"Diagnosis of primary biliary cirrhosis","volume":"25","author":"Hirschfield","year":"2011","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.ejim.2017.06.020_bb0010","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2017.06.020_bb0015","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL clinical practice guidelines: the diagnosis and of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2017.06.020_bb0020","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of cholestasis: from UDCA to FXR, PXR and beyond","volume":"62","author":"Beuers","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2017.06.020_bb0025","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/ncpgasthep0521","article-title":"Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis","volume":"3","author":"Beuers","year":"2006","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2017.06.020_bb0030","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/hep.23810","article-title":"The biliary HCO3\u2212 umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies","volume":"52","author":"Beuers","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.ejim.2017.06.020_bb0035","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S2210-7401(12)70015-3","article-title":"Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action","volume":"36","author":"Poupon","year":"2012","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.ejim.2017.06.020_bb0040","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/hep.1840110104","article-title":"Hepatic expression of class I and II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid","volume":"11","author":"Calmus","year":"1990","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2017.06.020_bb0045","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","article-title":"A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group","volume":"324","author":"Poupon","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2017.06.020_bb0050","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.gastro.2004.11.009","article-title":"The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis","volume":"128","author":"Corpechot","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2017.06.020_bb0055","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2017.06.020_bb0060","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1111\/j.1572-0241.2006.00699.x","article-title":"Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients","volume":"101","author":"Borg","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2017.06.020_bb0065","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","article-title":"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis","volume":"106","author":"Lindor","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2017.06.020_bb0070","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","article-title":"The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"19","author":"Heathcote","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2017.06.020_bb0075","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hep.510290301","article-title":"Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis","volume":"29","author":"Angulo","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2017.06.020_bb0080","first-page":"759","article-title":"A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"22","author":"Combes","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2017.06.020_bb0085","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/00365529709000190","article-title":"Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study","volume":"32","author":"Eriksson","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.ejim.2017.06.020_bb0090","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1572-0241.2002.05923.x","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial","volume":"97","author":"Papatheodoridis","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2017.06.020_bb0095","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0168-8278(00)80216-0","article-title":"Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver","volume":"32","author":"Par\u00e9s","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2017.06.020_bb0100","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1053\/jhep.2000.20240","article-title":"The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis","volume":"32","author":"Corpechot","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2017.06.020_bb0105","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1055\/s-2005-916323","article-title":"The natural history of PBC: has it changed?","volume":"25","author":"Lee","year":"2005","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.ejim.2017.06.020_bb0110","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2017.06.020_bb0115","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2017.06.020_bb0120","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2017.06.020_bb0125","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2017.06.020_bb0130","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/hep.26322","article-title":"Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study","volume":"58","author":"Zhang","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2017.06.020_bb0135","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jceh.2016.10.001","article-title":"Primary biliary cholangitis: disease pathogenesis and implications for established and novel therapeutics","volume":"4","author":"Patel","year":"2016","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.ejim.2017.06.020_bb0140","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jhep.2011.04.012","article-title":"A major step towards effective treatment evaluation in primary biliary cirrhosis","volume":"55","author":"Beuers","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2017.06.020_bb0145","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2017.06.020_bb0150","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2017.06.020_bb0155","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"issue":"14","key":"10.1016\/j.ejim.2017.06.020_bb0160","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.3892\/mmr.2016.5606","article-title":"Identification of microRNA profiles associated with refractory primary biliary cirrhosis","volume":"1","author":"Sakamoto","year":"2016","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.ejim.2017.06.020_bb0165","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1478-3231.2010.02366.x","article-title":"A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single centre","volume":"31","author":"Floreani","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.ejim.2017.06.020_bb0170","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2017.06.020_bb0175","doi-asserted-by":"crossref","first-page":"S805","DOI":"10.1016\/S0168-8278(15)31394-5","article-title":"Histological stage is relevant for risk stratification in primary biliary cirrhosis","volume":"62","author":"Carbone","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2017.06.020_bb0180","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jhep.2009.11.027","article-title":"Primary biliary cirrhosis: a 2010 update","volume":"52","author":"Poupon","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2017.06.020_bb0185","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","article-title":"Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial","volume":"117","author":"Leuschner","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2017.06.020_bb0190","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.510310209","article-title":"Oral budesonide in the treatment of patients with primary biliary cirrhosis with suboptimal response to ursodeoxycholic acid","volume":"31","author":"Angulo","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2017.06.020_bb0195","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20646","article-title":"Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial","volume":"41","author":"Rautianen","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2017.06.020_bb0200","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.gcb.2010.02.004","article-title":"Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone","volume":"34","author":"Rabahi","year":"2010","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.ejim.2017.06.020_bb0205","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/jhep.2003.50266","article-title":"Pharmacokinetics and pharmacodynamics action of budesonide in early- and late-stage primary biliary cirrhosis","volume":"38","author":"Hempfling","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2017.06.020_bb0210","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.18553\/jmcp.2016.22.10-a-s.s3","article-title":"Primary biliary cholangitis: medical and specialty pharmacy, management update","volume":"22","author":"Bowlus","year":"2016","journal-title":"JMCP"},{"key":"10.1016\/j.ejim.2017.06.020_bb0215","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/gut.2010.212159","article-title":"Farnesoid X receptor activation inhibits inflammation and preserves the interstitial barrier in inflammatory bowel disease","volume":"60","author":"Gadaleta","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.ejim.2017.06.020_bb0220","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/j.gastro.2011.10.028","article-title":"Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis","volume":"142","author":"Modica","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2017.06.020_bb0225","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hischfield","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2017.06.020_bb0230","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2017.06.020_bb0235","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/hep.28932","article-title":"Long-term clinical outcomes and cost-effectiveness of obeticholic acid for treatment of primary biliary cholangitis","volume":"65","author":"Samur","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2017.06.020_bb0240","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/hep.27744","article-title":"Fibrates and cholestasis","volume":"62","author":"Ghonem","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2017.06.020_bb0245","first-page":"2557","article-title":"Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis","volume":"9","author":"Zhang","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ejim.2017.06.020_bb0250","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/apt.13465","article-title":"Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes","volume":"43","author":"Cheung","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2017.06.020_bb0255","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/apt.13507","article-title":"Editorial: fenofibrate as second-line therapy in high risk PBC \u2013 more answers or more questions?","volume":"43","author":"Jones","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"1 (suppl)","key":"10.1016\/j.ejim.2017.06.020_bb0260","first-page":"108A","article-title":"Comparable beneficial effects of beza- and fenofibrate in primary biliary cholangitis. An international study in UDCA-treated individuals","volume":"64","author":"Harms","year":"2016","journal-title":"Hepatology"},{"issue":"S89","key":"10.1016\/j.ejim.2017.06.020_bb0265","first-page":"LBO-01","article-title":"A 2-year multicenter, double-blind, randomized, placebo-controlled study on bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso)","volume":"66","author":"Corpechot","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2017.06.020_bb0270","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/liv.12290","article-title":"Bezafibrates normalize alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid","volume":"34","author":"Lens","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.ejim.2017.06.020_bb0275","first-page":"1","article-title":"A non-tumorigenic variant of FGF19 treats cholestatic liver diseases","volume":"6","author":"Luo","year":"2014","journal-title":"Sci Trasl Med"},{"issue":"Suppl. 1","key":"10.1016\/j.ejim.2017.06.020_bb0280","first-page":"263A","article-title":"NGM282, a novel variant of FGF-19, demonstrates biologic activity in primary biliary cirrhosis patients with an incomplete response to ursodeoxycholic acid: results of a phase 2 multicenter, randomized, double blinded, placebo controlled trial","volume":"62","author":"Mayo","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2017.06.020_bb0285","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/hep.24748","article-title":"Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"55","author":"Tsuda","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2017.06.020_bb0290","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ajg.2013.51","article-title":"B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid","volume":"108","author":"Myers","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2017.06.020_bb0295","first-page":"5e007985","article-title":"RITPBC: B-cell depleting therapy (rituximab) as treatment for fatigue in primary biliary cirrhosis: study protocol for a randomized controlled trial","author":"Jopson","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejim.2017.06.020_bb0300","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hep.28359","article-title":"Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study","volume":"64","author":"Hirschfield","year":"2016","journal-title":"Hepatology"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620517302649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620517302649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T04:02:37Z","timestamp":1535688157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620517302649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":60,"alternative-id":["S0953620517302649"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2017.06.020","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary biliary cholangitis: Old and novel therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2017.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}